Web Exclusives

Advances in precision medicine and biomarker testing are transforming lung cancer treatment, offering hope through targeted therapies and innovative approaches.

With major reimbursement and coverage changes occurring in 2026, oncology practices are closely watching federal policy developments that could affect everything from prior authorization workflows to drug reimbursement and patient coverage stability.

It started with a bit of blood.

Although biomarker-driven targeted therapies for gastric cancer have advanced significantly, many eligible patients are not receiving these treatments, highlighting the urgent need to overcome barriers such as insufficient biomarker testing and socioeconomic disparities.

Iman Ahmed, PharmD, BCOP, recently discussed the evidence for what’s actually contributing to health inequities in hematologic malignancies, and how providers can mitigate these disparities.

Healthcare deserts are regions in the United States with limited access to healthcare providers and medicine, often contributing to poor health outcomes and healthcare inequities for residents of these communities.